MedPath

Investigation of the effect of Nimodipine on the treatment of resistant cutaneous leishmaniasis

Phase 2
Recruiting
Conditions
resistant cases of cutaneous leishmaniasis.
Cutaneous leishmaniasis
Registration Number
IRCT20160215026563N2
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
17
Inclusion Criteria

Age more than 18 years;
maximum lesion number is 4;
duration of illness is less than one year;
lesion type is dry Leishmaniasis (Clinical manifestation of urban leishmaniasis);
There are no sings of lymphangitis and sporotrichoid;
No more than 2 months has passed from the incidence of the lesion until wound formation;
there is no widespread wound and secretion.

Exclusion Criteria

having other atypical forms such as lupoid-sporotrichoid-erysipeloid-zoster forms and....;
patients who have had a heart attack within the last month;
patients with unstable angina;
patients with less than 100 spontaneous bacterial peritonitis (SBP) and consuming medications such as Azoles and Sodium Vauproat, and Macrolide and Fluoxetine due to the prohibition of Nimodipine use in these people;
incidence of drug complications during treatment such as Phlebitis, hypotension, headache, severe nausea and vomiting;
pregnancy;
breastfeeding;
the lesion is preferably not on the face.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in size and value of induration. Timepoint: Patients are evaluated every week until the end of treatment, one and a half months and three months after the end of the treatment. Method of measurement: Using caliper and measuring the diameter of lesion.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath